Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where HALO declined for three days, in 163 of 272 cases, the price declined further within the following month. The odds of a continued downward trend are 60%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HALO as a result. In 46 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 60%.
The Moving Average Convergence Divergence Histogram (MACD) for HALO turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 36 similar instances when the indicator turned negative. In 20 of the 36 cases the stock turned lower in the days that followed. This puts the odds of success at 56%.
HALO moved below its 50-day moving average on November 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +2.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where HALO advanced for three days, in 276 of 335 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
HALO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 257 of 328 cases where HALO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 14 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. HALO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: HALO's P/B Ratio (81.939) is slightly higher than the industry average of (3.498). P/E Ratio (29.192) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (7.968) is also within normal values, averaging (440.869).
INCY moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend. In 31 of 42 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 74%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where INCY's RSI Indicator exited the oversold zone, 24 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on INCY as a result. In 60 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.
The Moving Average Convergence Divergence (MACD) for INCY just turned positive on October 20, 2026. Looking at past instances where INCY's MACD turned positive, the stock continued to rise in 24 of 35 cases over the following month. The odds of a continued upward trend are 69%.
Following a +3.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where INCY advanced for three days, in 205 of 323 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 151 of 250 cases where INCY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 60%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INCY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
INCY broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Profit vs. Risk Rating rating for this company is 27 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 31 (best 1 - 100 worst), indicating outstanding price growth. INCY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 69 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.823) is normal, around the industry mean (3.498). P/E Ratio (14.717) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (10.822) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (4.401) is also within normal values, averaging (440.869).
HALO | INCY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 82 | 20 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 98 Overvalued | 92 Overvalued | |
PROFIT vs RISK RATING 1..100 | 14 | 27 | |
SMR RATING 1..100 | 11 | 33 | |
PRICE GROWTH RATING 1..100 | 42 | 31 | |
P/E GROWTH RATING 1..100 | 5 | 69 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
INCY's Valuation (92) in the Biotechnology industry is in the same range as HALO (98). This means that INCY’s stock grew similarly to HALO’s over the last 12 months.
HALO's Profit vs Risk Rating (14) in the Biotechnology industry is in the same range as INCY (27). This means that HALO’s stock grew similarly to INCY’s over the last 12 months.
HALO's SMR Rating (11) in the Biotechnology industry is in the same range as INCY (33). This means that HALO’s stock grew similarly to INCY’s over the last 12 months.
INCY's Price Growth Rating (31) in the Biotechnology industry is in the same range as HALO (42). This means that INCY’s stock grew similarly to HALO’s over the last 12 months.
HALO's P/E Growth Rating (5) in the Biotechnology industry is somewhat better than the same rating for INCY (69). This means that HALO’s stock grew somewhat faster than INCY’s over the last 12 months.
| HALO | INCY | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 87% | 2 days ago 71% |
| Stochastic ODDS (%) | 2 days ago 85% | 2 days ago 54% |
| Momentum ODDS (%) | 2 days ago 60% | 2 days ago 64% |
| MACD ODDS (%) | 2 days ago 56% | 2 days ago 69% |
| TrendWeek ODDS (%) | 2 days ago 61% | 2 days ago 65% |
| TrendMonth ODDS (%) | 2 days ago 64% | 2 days ago 64% |
| Advances ODDS (%) | 14 days ago 82% | 3 days ago 63% |
| Declines ODDS (%) | 3 days ago 60% | 9 days ago 56% |
| BollingerBands ODDS (%) | 2 days ago 86% | 2 days ago 55% |
| Aroon ODDS (%) | 2 days ago 78% | 2 days ago 60% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
HALO’s FA Score shows that 3 FA rating(s) are green while INCY’s FA Score has 3 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
HALO’s TA Score shows that 5 TA indicator(s) are bullish while INCY’s TA Score has 6 bullish TA indicator(s).
HALO (@Biotechnology) experienced а -19.93% price change this week, while INCY (@Biotechnology) price change was +2.30% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
HALO is expected to report earnings on Feb 23, 2027.
INCY is expected to report earnings on Feb 09, 2027.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| 1 Day | |||
|---|---|---|---|
| CRYPTO / NAME | Price $ | Chg $ | Chg % |
| XAI.X | 0.006212 | 0.000033 | +0.54% |
| Xai cryptocurrency | |||
| XTJA | 34.79 | N/A | N/A |
| Innovator U.S. Equity Accelerated Plus ETF - January (XTJA) | |||
| RLC.X | 0.411509 | -0.000069 | -0.02% |
| iExec RLC cryptocurrency | |||
| REI.X | 0.001590 | -0.000008 | -0.52% |
| REI Network cryptocurrency | |||
| BETH.X | 2047.152600 | -84.104004 | -3.95% |
| Beacon ETH cryptocurrency | |||